Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Browse Research
  • Browse News
  • About Our Research
  • Transplant Enews

Transplant Enews

  • Advances in Transplant Enews
  • Resource Connection Enews
  • Research and News
  • Transplant Enews
  • Resource Connection Enews
  • Survivorship care plans reduce treatment distress for BMT recipients
  • Email
  • Print This Page

Survivorship care plans reduce treatment distress for BMT recipients

Survivorship Care Plans

A recent study conducted by National Marrow Donor Program® (NMDP®)/Be The Match® based on a grant from the Patient-Centered Outcomes Research Institute (PCORI) looked at the feasibility and effectiveness of survivorship care plans (SCPs) created from a centralized registry of clinical data. [1]

Study Details and Results

The researchers enrolled 495 patients 1 – 5 years after an allogeneic transplant from 17 different transplant centers and randomized them to either an individualized SCP or standard care. The SCPs were generated using patient-specific clinical data reported to the CIBMTR® (Center for International Blood and Marrow Transplant Research®) and published guidelines for long-term follow-up of BMT survivors.[1] A total of 458 patients completed the study. The researchers measured distress specific to cancer and its treatment, knowledge of transplant exposures, health behaviors, health care utilization and health-related self-efficacy. They found that having an SCP was associated with less cancer treatment distress six months after implementing the care plan. They also found that younger patients tended to have higher levels of distress than older patients.

The future of SCPs in BMT

The Commission on Cancer implementation schedule requires SCPs for at least 75% of eligible patients in 2018. However, even with the standard in place, further study of SCPs is needed in the following areas:

  • The best format and delivery for SCPs
  • Their effects on clinical and patient-reported outcomes
  • How best to use them to improve communication and care coordination

“Transplant survivors remain at risk for late complications and require lifelong monitoring for their prevention and management,” said Navneet Majhail, M.D., M.S., lead study author and director of the Blood & Bone Marrow Program at the Cleveland Clinic. “However, several health system, institutional, provider and patient barriers prevent them from obtaining appropriate long-term care. We strongly feel that empowering patients with knowledge and information will facilitate their survivorship care.”

Practical strategies are needed to overcome common barriers to SCP implementation, such as the time-intensive process to create meaningful, individualized SCPs. This study used the CIBMTR centralized registry of clinical data that transplant centers report patient data to for systematic development of individualized SCPs. This highlights the potential for using existing systems to make individualized SCPs feasible for all allogeneic BMT recipients. 

Resources for you and your patients

In 2012, BMT experts published recommended screening and preventive practice guidelines for autologous and allogeneic transplant recipients.[2] Access the free, user-friendly guidelines in a mobile app, online or print:

For you: BeTheMatchClinical.org/guidelines

For your patients: BeTheMatch.org/careguide

About PCORI

The Patient-Centered Outcomes Research Institute (PCORI) is an independent nonprofit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work

References

1. Majhail, N. S., Murphy, E. A., Laud, P., Preussler, J., Denzen, E., Adams, A., … Baker, K. S. (2017, December). Individualized Treatment Summaries and Survivorship Care Plans (SCPs) for Hematopoietic Cell Transplant (HCT) Survivors Reduces Cancer Treatment Distress in a Randomized, Multicenter Study. Paper presented at the 59th meeting of the American Society of Hematology, Atlanta, GA. Access

2.  Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., . . . Tichelli, A. (2012). Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 18(3), 348-371. http://dx.doi.org/10.1016/j.bbmt.2011.12.519. Access

 

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright